Top 10 Merchant Account Providers for Peptides in Australia

Before comparing a single payment provider, Australian peptide businesses need to understand something that genuinely sets this market apart from the US or UK equivalents covered elsewhere in this series: Australia’s Therapeutic Goods Administration applies a more restrictive regulatory framework to peptides than any other major English-speaking country. BPC-157 — arguably the single most searched research peptide globally — was reclassified to Schedule 4 (prescription-only) under the Poisons Standard in March 2025. Semaglutide, tirzepatide, liraglutide, MK-677, GHRP-2, GHRP-6, CJC-1295, ipamorelin, and hexarelin all currently sit under Schedule 4 as well, and Melanotan II is prohibited outright under Schedule 9. Importing a Schedule 4 peptide without a valid Australian prescription and the required import authority can result in fines exceeding AUD $200,000, and the TGA tightened personal importation enforcement further in February 2026, now requiring formal declarations of intended use on all peptide imports.

This changes what “payment processing for peptides” actually means in the Australian context. A business model that works cleanly in the US under research-use labeling can be operating outside the law entirely in Australia if its catalog includes now-scheduled compounds sold to Australian consumers without proper authorization. This guide covers payment processing specifically for businesses operating within Australia’s actual legal framework — genuinely unscheduled research compounds, licensed institutional supply, and prescription-pathway-compliant models — not a workaround guide for restricted substances.

How This List Was Built

We weighted genuine international peptide underwriting experience with explicit AUD currency support, since no major payment provider in this research is Australia-headquartered specifically — worth being upfront about, since the realistic options for Australian peptide businesses are international specialists rather than local ones. We also weighted documentation support for the TGA-specific compliance dimension this market requires, given how much more consequential scheduling status is here than in most comparable jurisdictions.

1. QuadraPay — Explicit AUD Support Built Into Multi-Currency Peptide Processing

QuadraPay specifically lists AUD alongside USD, EUR, GBP, and CAD as a supported settlement currency for peptide merchant accounts, with multilingual checkout page support and a stated focus on genuine peptide merchants seeking global transaction acceptance. For Australian peptide businesses wanting explicit currency-level confirmation before applying, QuadraPay’s direct AUD listing is a meaningful starting signal that most competitors don’t make as explicit.

Best for: Australian peptide businesses wanting confirmed, explicit AUD settlement support rather than assuming general international coverage extends to their currency.

2. Unison Payment Solutions — Transparent Approval Metrics With Documented Case Outcomes

Unison Payment Solutions reports merchant account approval rates exceeding 80% for prepared applications, with card authorization rates separately reaching 96%+ for properly configured accounts, and publishes documented case outcomes (one cited example: a peptide merchant declined five times elsewhere, approved in 3 business days with a 0.4% chargeback ratio and $45,000+ monthly revenue restored after matching). For Australian businesses that have struggled with approval elsewhere, this transparency about real outcomes is worth weighing seriously.

Best for: Australian peptide businesses that have faced prior declines wanting a provider with documented, transparent recovery case outcomes.

3. Durango Merchant Services — Genuine Multi-Currency Infrastructure Across 200+ Countries

Durango enables acceptance of 26 international currencies across more than 200 countries, with gateway localization in up to 15 languages and both fixed and variable currency conversion options — infrastructure genuinely built for international reach rather than a US-first setup with AUD support added as an afterthought. Its mixed but often positive reputation specifically emphasizes helping businesses that were declined elsewhere, with strong communication throughout the underwriting process.

Best for: Australian peptide businesses wanting genuinely broad multi-currency infrastructure rather than a narrower AUD-specific add-on.

4. PaymentCloud — Broad High-Risk Placement With Nutraceutical-Specific Gateway Tools

PaymentCloud offers payment gateways designed specifically for nutraceutical and peptide-adjacent ecommerce businesses, supporting both subscription and one-time purchase models with point-of-sale options for any Australian peptide business with a physical or clinic-adjacent presence alongside online sales.

Best for: Australian peptide businesses with both online and in-person sales channels, such as clinic-adjacent operations, wanting unified payment tooling across both.

5. SoarPay — Balanced Underwriting Extending to International Nutraceutical Categories

SoarPay’s support for nutraceuticals alongside CBD and subscription-based ecommerce, combined with dedicated account managers and customized account setups, extends usefully to Australian peptide businesses with genuinely compliant, operationally clean risk profiles — though it’s worth confirming AUD settlement capability directly given SoarPay’s primary market focus.

Best for: Australian peptide businesses with clean, compliant risk profiles wanting dedicated account management from an established nutraceutical-experienced provider.

6. AllayPay — Domestic-Model Expertise Worth Evaluating for Compliance Structuring

AllayPay’s expertise in structuring research-use-only positioning and FDA-adjacent compliance documentation, while built primarily around the US regulatory context, offers a useful template for the kind of rigorous compliance documentation Australian peptide businesses need to assemble given the TGA’s even stricter scheduling framework — worth engaging specifically for its compliance-structuring expertise even if its primary domestic processing is US-focused.

Best for: Australian peptide businesses wanting to learn from AllayPay’s compliance documentation approach, best paired with confirmed AUD settlement through another provider on this list.

7. Instabill — Offshore Structuring Option for Complex Australian Risk Profiles

Instabill specifically offers offshore merchant account structuring as an option for high-risk industries including research chemicals, with fast application turnaround and PCI compliance resources built in. For Australian peptide businesses whose risk profile or product catalog makes domestic-equivalent placement difficult, Instabill’s offshore option is worth evaluating as a structural alternative — though offshore structuring adds its own tax and regulatory reporting complexity worth weighing against the approval benefit.

Best for: Australian peptide businesses with a complex risk profile considering offshore merchant account structuring as an alternative approval path.

8. Bankcard International Group (BIG) — Long-Term Stability Over Fast Approval

Bankcard International Group positions itself specifically around supporting legitimate, compliant nutraceutical and supplement businesses over the long term, with tailored underwriting and banking relationships built for stability rather than a fast-approval-then-termination cycle — a genuinely relevant positioning given how much more scrutiny Australian peptide businesses face on an ongoing basis as the TGA’s Poisons Standard continues to update quarterly.

Best for: Australian peptide businesses prioritizing long-term account stability given the TGA’s regularly updated scheduling framework.

9. SecureGlobalPay — Multi-Account Load Balancing for High-Volume Australian Operations

SecureGlobalPay’s ability to manage multiple merchant accounts from a single gateway with advanced transaction routing and load balancing is particularly relevant for larger Australian peptide operations — B2B wholesalers or multi-brand operators — wanting redundancy built into the payment infrastructure itself rather than manually managing separate relationships.

Best for: Larger Australian peptide operations, including B2B wholesalers, wanting built-in multi-account load balancing.

10. PayFac Solutions — Crypto-Friendly Global Processing as a Compliance-Adjacent Alternative

PayFac Solutions’ crypto-friendly, global payment infrastructure offers Australian peptide businesses an alternative settlement rail worth considering specifically for its global reach, though — as with any crypto settlement option — this doesn’t change the underlying TGA compliance obligations around what can legally be sold and imported into Australia in the first place.

Best for: Australian peptide businesses wanting a crypto-inclusive global processing option as one part of a diversified payment stack.

Side-by-Side Snapshot

Why Australia’s Regulatory Framework Changes the Payment Risk Calculation Entirely

Most popular research peptides are now prescription-only in Australia, not merely “high-risk” from a payments perspective. BPC-157’s March 2025 rescheduling to Schedule 4 moved it from a genuine grey zone — where enforcement was inconsistent and many suppliers and consumers interpreted it as permissible — to unambiguous prescription-only status, a legal change with real consequences beyond just payment processor risk appetite.

The TGA’s enforcement activity is real, documented, and financially significant. A Victorian individual was fined $3,756 in April 2024 for importing an unapproved peptide, followed by a further $11,268 in infringement notices in September 2025 for additional unauthorized imports, and Peptide Clinics Australia Pty Ltd was hit with a $10 million Federal Court penalty in 2019 specifically for advertising breaches — this is not a jurisdiction where enforcement is theoretical.

February 2026 personal importation tightening adds further scrutiny. New TGA rules require formal declarations of intended use on all peptide imports, automatically flag quantities over three months’ personal supply for inspection, and expanded the prohibited peptide list to include additional growth hormone secretagogues — a direct response to a 2025 review that found increasing diversion of research peptides into clinical and performance-enhancement use.

Payment processors serving Australian peptide businesses need to underwrite against this specific regulatory backdrop, not a generic high-risk template. A processor comfortable with US research-use-only positioning may not have the specific familiarity with the Poisons Standard needed to properly assess whether an Australian-facing peptide catalog is actually compliant — which is exactly why documentation and compliance structuring matter more in this market than almost anywhere else in this series.

What Actually Remains Legally Sellable in the Australian Market

Most compounds commonly discussed in the international research peptide market remain unscheduled in Australia specifically. GHK-Cu, Retatrutide, NAD+, Semax, Selank, Epithalon, KPV, MOTS-c, and SS-31 are not currently listed in the Poisons Standard, according to current compliance guidance — though the Poisons Standard updates quarterly, meaning any specific compound’s status needs to be verified against the current instrument rather than assumed static.

Licensed research institution supply operates under a different framework entirely. Section 19 exemption permits allow supply to licensed research institutions specifically, though the TGA does not grant these to individuals without documented institutional affiliation — a business model genuinely distinct from direct-to-consumer sales and worth structuring separately in any payment application.

Domestic Australian supply avoids importation risk entirely, which is itself a meaningful business model distinction. Suppliers sourcing and compounding within Australia sidestep the import permit, customs declaration, and Border Force screening risk that affects any business importing peptides from overseas — a structural advantage worth highlighting explicitly to payment underwriters evaluating an Australian peptide business’s overall risk profile.

Fee and Documentation Benchmarks Specific to This Market

None of the providers on this list publish flat AUD-specific rate cards, since international specialists price Australian peptide applications on the same individualized underwriting basis they apply to any market — expect a consultation and custom quote rather than a published rate, with the additional step of confirming AUD settlement mechanics explicitly during that conversation.

Reserve structures for Australian peptide merchants may run higher than equivalent US or UK applications given the added TGA scheduling complexity a provider needs to underwrite around. This isn’t a fixed rule across every provider, but it’s a realistic expectation worth planning for, particularly for newer businesses without an established processing history specific to the Australian market.

Currency conversion costs deserve explicit attention given how few providers on this list are AUD-native. Even where AUD settlement is supported, confirm the specific FX margin applied to any conversion step, since this cost compounds meaningfully for a business processing consistent monthly volume and can vary noticeably between providers offering nominally similar AUD support.

The Documentation Package Australian Peptide Businesses Actually Need

Current Poisons Standard verification for every product in the catalog, checked against the most recent quarterly update, not a snapshot taken at business launch. Since scheduling changes have moved previously unscheduled compounds (BPC-157 being the clearest recent example) into Schedule 4 status, a catalog that was fully compliant a year ago may no longer be, making this the single most time-sensitive compliance check specific to the Australian market.

Clear separation of business model — direct-to-consumer, institutional Section 19 supply, or domestic-only sourcing — documented explicitly rather than blended together. Since these represent genuinely different regulatory pathways, a payment application that doesn’t clearly distinguish which model applies to which portion of revenue creates exactly the kind of ambiguity that slows underwriting or triggers later account review.

Advertising and marketing content audited against the Therapeutic Goods Advertising Code specifically, given the real financial consequences documented in enforcement history — this is a distinct compliance check from the product-scheduling review, covering how products are described and marketed rather than just which specific compounds are sold.

Import documentation (Material Safety Data Sheets, ODC permits where applicable) organized and ready to produce, since underwriters serving genuinely compliant Australian peptide businesses will want evidence that import processes match what current TGA requirements demand, not just a general compliance statement.

Frequently Asked Questions

1. Which commonly discussed research peptides are now Schedule 4 (prescription-only) in Australia? Current Schedule 4 peptides include semaglutide, tirzepatide, liraglutide, MK-677 (ibutamoren), BPC-157 (rescheduled March 2025), GHRP-2, GHRP-6, CJC-1295, ipamorelin, and hexarelin, with the Poisons Standard updated quarterly meaning this list can expand further.

2. What penalty can Australian peptide importers face for unauthorized imports? Importing a Schedule 4 peptide without a valid Australian prescription and required import authority can result in fines exceeding AUD $200,000, and real enforcement cases include a Victorian individual fined a combined $15,024 across 2024 and 2025 infringement notices.

3. When was BPC-157 rescheduled in Australia, and what changed? BPC-157 was added to Schedule 4 of the Poisons Standard in March 2025, moving it from an ambiguous grey-zone status — where it was commonly sold as a “research chemical” — to unambiguous prescription-only status.

4. What new import restrictions did the TGA introduce in February 2026? The TGA introduced stricter enforcement requiring formal declarations of intended use on all peptide imports, with quantities over three months’ personal supply automatically flagged for inspection, alongside an expanded list of prohibited growth hormone secretagogues.

5. Which payment providers explicitly support AUD for peptide merchant accounts? QuadraPay specifically lists AUD alongside USD, EUR, GBP, and CAD as a supported settlement currency, while Durango Merchant Services offers broader multi-currency infrastructure across 26 currencies and 200+ countries that should be confirmed to include AUD directly.

6. Are there any Australia-headquartered payment providers specializing in peptide merchant accounts? Based on available research, the realistic options for Australian peptide businesses are international specialists with AUD support rather than Australia-headquartered peptide payment specialists specifically — worth confirming AUD settlement and Australian compliance familiarity directly with any provider before applying.

7. What penalty did Peptide Clinics Australia face, and why does it matter for payment underwriting? Peptide Clinics Australia Pty Ltd received a $10 million Federal Court penalty in 2019 specifically for advertising breaches under the Therapeutic Goods Advertising Code — a reminder that marketing language compliance carries real financial consequences in Australia beyond payment processor account risk alone.

8. Which research peptides remain unscheduled and legally sellable in Australia? Compounds including GHK-Cu, Retatrutide, NAD+, Semax, Selank, Epithalon, KPV, MOTS-c, and SS-31 are not currently listed in the Poisons Standard according to current guidance, though the Poisons Standard updates quarterly and any specific compound’s status should be verified against the current instrument.

9. What is a Section 19 permit, and how does it affect Australian peptide payment processing? A Section 19 exemption permit allows supply to licensed research institutions specifically, granted only to businesses with documented institutional affiliation — this represents a genuinely different business model from direct-to-consumer sales and should be structured and documented separately in any payment provider application.

10. Does selling only domestically within Australia reduce peptide payment processing risk? Yes, meaningfully — domestic Australian supply avoids the import permit, customs declaration, and Border Force screening risk that affects any business importing peptides from overseas, a structural risk-profile advantage worth explicitly highlighting to payment underwriters evaluating an Australian peptide business.

Final Verdict

For Australian peptide businesses, this guide comes with a caveat none of the other jurisdictions in this series require as strongly: payment processor selection is secondary to confirming your actual product catalog’s legal status under the current Poisons Standard first. Once that compliance foundation is genuinely solid — unscheduled compounds only, or a properly structured Section 19 institutional supply model, or domestic-only sourcing that avoids import risk entirely — QuadraPay’s explicit AUD support and Durango’s broad multi-currency infrastructure make the strongest starting points among international specialists. Businesses with prior declines should weight Unison’s documented recovery outcomes heavily, while larger B2B or multi-brand operations should evaluate SecureGlobalPay’s load-balancing infrastructure. Given how actively the TGA has enforced against both unauthorized imports and advertising breaches, treat compliance documentation — proof of unscheduled status, institutional affiliation where relevant, and advertising language that avoids any therapeutic claim — as the actual foundation this entire payment processing decision rests on, not an afterthought to handle once a provider is already in place.